Related Experiment Video
Updated: Jul 8, 2025
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Mendelian randomization analysis to elucidate the causal relationship between small molecule metabolites and ovarian
Xin Chang1,2, Shijia Liu1,2, Lu Han1
1Department of Gynecology, Dalian Women and Children's Medical Group, Dalian, Liaoning, China.
Background:
Small molecule metabolites are potential biomarkers for ovarian cancer. However, the causal relationship between small molecule metabolites and ovarian cancer remains unclear.
Methods:
Single nucleotide polymorphisms (SNPs) correlated with 53 distinct small molecule metabolites were identified as instrumental variables (IVs) from comprehensive genome-wide association studies. Aggregate data encompassing 25,509 cases of ovarian cancer and 40,941 controls of European descent were procured from the Ovarian Cancer Association Consortium. To evaluate causative associations, four Mendelian randomization techniques-including inverse-variance weighted, weighted median, maximum likelihood, and MR-Egger regression-were employed.
Results:
In total, 242 SNPs were delineated as IVs for the small molecule metabolites under consideration. A significant association with the overarching risk of ovarian cancer was observed for six distinct metabolites. Hexadecenoylcarnitine and methioninesulfoxide were associated with a 32% and 31% reduced risk, respectively. Fifteen metabolites were linked to subtype ovarian cancers. For instance, both methionine sulfoxide and tetradecanoyl carnitine exhibited an inverse association with the risk of clear cell and high-grade serous ovarian cancers. Conversely, tryptophan demonstrated a 1.72-fold elevated risk for endometrioid ovarian cancer.
Conclusion:
This study identified several metabolites with putative causal effects on ovarian cancer risk using Mendelian randomization analysis. The findings provide insight into the etiological role of small molecule metabolites and highlight potential early detection biomarkers for ovarian cancer. Subsequent investigations are imperative to corroborate these findings and elucidate the underlying pathophysiological mechanisms.
